StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen deferred tax liabilities ($M) ($M)

Form 10-K (DB)

QuarterlyAnnual
Latest, Q2 2026
1,301
Period ended Jun 30, 2026
Change on a year earlier
-6.1%
1,386 in Q2 2025
History
37 quarters
Since Q4 2012
Sources
35
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDeferred tax liabilities ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,301-6.1%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20261,344-11.0%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 20251,366-15.5%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 20251,458-14.8%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20251,386-22.1%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 20251,510-18.9%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 20241,616-31.4%Form 10-K (filed 2025-02-14) ↗
Q3 2024Sep 30, 20241,711–Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 20241,780–Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 20241,862–Form 10-Q (filed 2024-05-03) ↗
Q4 2023Dec 31, 20232,354+21,300.0%Form 10-K (filed 2024-02-14) ↗
Q4 2022Dec 31, 202211–Form 10-K (filed 2024-02-14) ↗
Q3 2020Sep 30, 2020210–Form 10-Q (filed 2020-10-29) ↗
Q2 2020Jun 30, 2020259-66.1%Form 10-Q (filed 2020-07-29) ↗
Q1 2020Mar 31, 2020427-47.3%Form 10-Q (filed 2020-05-01) ↗
Q4 2019Dec 31, 2019606-29.9%Form 10-K (filed 2020-02-12) ↗

Cite this data

StockData. (2026). Amgen Deferred tax liabilities ($M) ($M), quarterly Q4 2012–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_dtl

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.